[ad_1]
The results of the third phase show that the vaccine invented by the American pharmaceutical company Pfizer and the German biotechnology company Bioentech is 95 percent effective against the corona. Early last week, the initial results of this step were reported to be more than 90 percent effective. Pfizer says the vaccine meets the necessary safety standards. An emergency approval request will be submitted to the US Food and Drug Administration shortly.
Analysis of the efficacy of the vaccine showed that 95 percent of the volunteers were protected from the virus within 28 days of administering the first dose. It has been shown to be 94 percent effective in people over 65. No serious bad news was found after receiving the vaccine. There is no concern for your safety. Of the 43,000 vaccinators, only 2 percent had headaches and 3.6 percent had fatigue.
Meanwhile, pilot programs for the experimental delivery of Pfizer vaccines have been launched in the US states of Island, Texas, New Mexico and Tennessee, but the problem in this delivery process is temperature. Vaccines invented by Pfizer should be stored at minus 60 degrees Celsius. Other common vaccines are kept between 2 and 6 degrees Celsius. In this case, the Pfizer vaccine can be difficult to obtain from the usual drug distributors.
Pfizer said in a statement: “The Ticker Pilot Program has been launched. We hope this will serve as a model for other US states and international governments.”
On Monday, the American biotech company Moderna claimed that the coronavirus vaccine was 94.5 percent effective. Modern claims this based on preliminary results after testing the third stage of that vaccine. Approximately 30,000 volunteers from the United States participated in the final test of the Modern Ticker. The Russian Spink V vaccine is 92 percent effective, according to the Tas news agency.
Coronavac is also successful: China’s Sinovac Biotech Coronavac vaccine has been successful in medium-term trials, researchers say. Trials of more than 600 people have shown that vaccines rapidly increase immunity.
Four potential vaccines from China have entered the final stages of clinical trials, including the Sinovac Biotech vaccine. However, the results of the first and second round of trials of the vaccine have only been published in the scientific journal Lancet.
Xu Fengchai, one of the authors of the research report published in The Lancet, said that the results of the vaccine, which was administered to 144 people in the first phase and 600 people in the second phase, showed that the vaccine was “suitable for emergency use “. Source: Reuters, BBC.
[ad_2]
